A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ankylosing spondylitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jun 2017 Results of a post hoc analysis (n=207) assessing the correlation between tofactinib treatment and minimally important changes in MRI sacroiliac joint and spine scores presented at the 18th Annual Congress of the European League Against Rheumatism
    • 10 Jun 2017 Biomarkers information updated
    • 27 Jan 2017 Results assessing efficacy and safety published in the Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top